Scott Carmer is the former CEO at NexImmune – a Johns Hopkins incubated spin-out which was based on innovative science developed in the lab of co-founder, Jonathan Schneck. During an eight-year career at NEXI, Scott helped to raise over $75M in Series A financing, grew the Company from 8 to 75 employees, and took the Company public in Feb. 2021 through an oversubscribed $125M IPO. Prior to NEXI, Scott held Sr/Executive Leadership positions at Amgen, Genentech, MedImmune and AstraZeneca where he maintained responsibilities across the continuum of drug development and commercialization. Scott is back at it again . . . this time, working with founding scientists at JHU to spin-out another start-up company developing biomarker-conjugated nanoparticles for the treatment of T1D.